Arcus Biosciences Announces First Quarter 2018 Financial Results and Recent Corporate Updates
Arcus Biosciences Presents Phase 1 Data for AB928 in Healthy Volunteers at 2018 AACR Annual Meeting
AB928 is a potent and selective dual antagonist of the adenosine receptors known as A2aR and A2bR.
AB154 is a monoclonal antibody (mAb) that potently and selectively blocks a novel immune checkpoint called TIGIT.
AB122 is a monoclonal antibody (mAb) that potently and selectively blocks a protein called PD-1.
AB680 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine.